We've got a lot to go over, so let's not waste another second.

StockWireNews

Staring Down The Opening Bell, Nasdaq Past Champ (ALBT) Needs Full Attention After Tuesday's Huge Patent News

January 18th

Greetings Readers,

We've got a lot to go over, so let's not waste another second.

Right now, we've got a 5X Nasdaq past champ back on radar.

On 5 separate occasions over the past 12 month stretch, I've brought this profile to your attention.

Each time it made an approximate 20% or more short term or intraday run.

Most recently, I brought it to your attention at the end of December.

Within 2 weeks? It had run from an alert day open of $.45 to an early January high of $.6051 for a short term surge of approximately 34%.

Now, here's where things get interesting...

Since that time, this profile has gone through a share restructuring and a 1:10 st-ock split.

So why is that interesting? Because this. It has made this Nasdaq profile a much more volatile idea with explosive intraday potential based on its low float under 4Mn shares.

Pair that knowledge with the fact that this company has come out hot in January with a handful of major announcements including Tuesday's incredible patent news, and you can see why this profile's oversold leaning technicals could make it ripe for potential reversal.

For Wednesday, get this 5X Nasdaq past champ back on radar:

*Avalon GloboCare Corp. (ALBT)*

Avalon GloboCare Corp. (Former ticker "AVCO") is a clinical-stage, vertically integrated, leading CellTech bio-developer dedicated to advancing and empowering innovative, transformative immune effector cell therapy, exosome-based ACTEX technology, as well as cell therapy related companion diagnostics.

And right now, ALBT has several potential breakout catalysts that are must-know material. Check them out:

No. 1 - Tuesday's Game-Changing Patent News Has So Far Gone Under The Radar...

No. 2 - A Low Float Could Allow For Explosive Volatility (Daily)

No. 3 - Company's Fusion Gene Map Technology Seen As Major Breakthrough

No. 4 - Oversold Technicals Could Signal Huge Bounce Potential Near Term

But more on those in a second...

Avalon GloboCare’s Revolutionary Research

Avalon is a clinical-stage, vertically integrated, leading “CellTech” bio-developer dedicated to advancing and empowering innovative, transformative immune effector cell therapy, exosome technology, as well related diagnostics and therapeutics.

image

The Company also provides strategic advisory and outsourcing services to facilitate and enhance its clients’ growth and development, as well as competitiveness in healthcare and CellTech industry markets.

Through its subsidiary structure with unique integration of verticals from innovative R&D to automated bioproduction and accelerated clinical development, the Company is establishing a leading role in the fields of cellular immunotherapy (including CAR-T/NK), exosome technology (ACTEX™), and other related vaccine and therapeutics.

Their core focus, at the moment, is their 3rd Generation CAR-T therapy that can potentially be useful in the treatment of cancer and other life-threatening diseases along with their FLASH-CAR technology and stem cell derived Exosome technology called ACTEX. ACTEX can be used to treat a wide variety of conditions, from neurodegenerative disorders to immune health, orthopedic applications, wound management, and even weight management.

The “QTY Code” Breakthrough Technology

Avalon recently announced a new research study applying artificial intelligence (AI) enhanced protein design “QTY Code” technology. The method is expected to accelerate the development of therapeutic monoclonal antibodies to treat cancer.

The research demonstrates a novel method for quickly predicting the design of so-called “water-loving” or hydrophilic variant structures of the 14 glucose transport membrane proteins in cells, which allows researchers to study the proteins more easily in water. Glucose transport membrane proteins are deregulated in many tumor types and are a potentially important target for cancer therapy.

The “QTY Code” breakthrough technology, developed by Avalon and the laboratory of Dr. Shuguang Zhang, Ph.D. MIT’s Media Lab in Boston, MA, is a protein-design platform that can turn water-insoluble transmembrane receptor proteins into water-soluble proteins, enabling their use in many clinical applications, including drug development.

A team of scientists led by Dr. Zhang applied the QTY code to the 14 glucose transport membrane proteins that transport sugar to cells. They used Google’s AlphaFold2, a DeepMind AI program, which can accurately and quickly predict how proteins fold. Dr. Zhang and his team used the QTY code with the open-source AlphaFold2 to predict the structures of these proteins in both their natural hydrophobic shapes and their QTY-code altered water-soluble shapes.

Click here for more QTY code info.

Avalon Files To Protect “IP”

Recently, Avalon jointly filed 16 patent applications, and co-invented with key strategic partners, including a top-5 U.S. university, a leading education and research center in Europe, as well as a premier multi-national developer of cellular therapies in the field of oncology. Patents were filed with the U.S. Patent and Trademark Office (USPTO), the China National Intellectual Property Administration (CNIPA), and under the Patent Cooperation Treaty (PCT) covering 36 countries.

The new intellectual property covers three core patent families:

Engineering and bio-manufacturing of novel CAR T-cells related to the mRNA-based Flash-CARTM cellular therapy platform. This technology has been applied to Avalon’s AVA-011 CAR-T cell therapy candidate, which is currently at the process development stage to generate cGMP-grade CAR-T cells for upcoming first-in-human clinical trials.

Soluble, antibody-like cytokine/chemokine decoy receptors derived from the QTY protein design, with potential applications including mitigation of the “cytokine storm” associated with CV-19 and cellular immunotherapy delivery, as well as broadening the range of therapeutic targets addressable by CAR T-cell therapies.

Novel S-layer coated emulsome technology (SLET)-derived fusion proteins intended for mucosal vaccine development, which are designed to trigger robust protective immune responses at the predominant sites of pathogen infection. The SLET platform provides a “molecular GPS system” to guide the trafficking and delivery of a payload to a targeted destination in the body.

Find more patent info here.

-----

And right now, multiple potential catalysts could once again fuel a vertical chart move in the near term for ALBT. They are:

No. 1 ALBT Potential Catalyst - Tuesday's Game-Changing Patent News Has So Far Gone Under The Radar...

Avalon GloboCare Announces Issuance of Key U.S. Patent for Multiple Novel QTY-Code Modified Cytokine and Chemokine Protein Receptor Molecules

Patent Jointly Filed with the Massachusetts Institute of Technology (MIT)

FREEHOLD, N.J., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a leading global developer of innovative cell-based technologies and therapeutics and laboratory testing provider, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,555,060, titled “QTY Fc Fusion Water Soluble Receptor Proteins.” The issued claims cover the composition of matter and methodology for multiple novel QTY-code modified cytokine and chemokine protein receptor molecules. The patent was jointly filed with Dr. Shuguang Zhang of the Massachusetts Institute of Technology (MIT).

...

We are pleased to be granted this key patent by the USPTO which expands our intellectual property portfolio,” stated David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon GloboCare. “We have jointly filed 16 patent applications, co-invented with key strategic partners, including a top-5 U.S. university, a leading education and research center in Europe, as well as a premier multi-national developer of cellular therapies in the field of oncology, and this issuance further enhances our position as a leader in immuno-oncology and cellular medicines.

The QTY code protein design platform, which was developed together with Professor Shuguang Zhang’s laboratory at MIT, can turn water-insoluble proteins that normally reside within cellular membranes—and that can be difficult to work within the laboratory—into water-soluble proteins that can be potentially used in many clinical applications. The resulting soluble, antibody-like cytokine/chemokine decoy receptors derived using the QTY protein design, have many potential applications including mitigation of the 'cytokine storm' associated with CV-19 and cellular immunotherapy delivery, as well as broadening the range of therapeutic targets addressable by CAR T-cell therapies,” concluded Dr. Jin.

Read the full article here.

-----

No. 2 ALBT Potential Catalyst - A Low Float Could Allow For Explosive Volatility (Daily)

According to the Yahoo Finance website, ALBT has a low float.

The website reports this profile to have approximately 3.22Mn shares in its float.

Why is that important? It's important on one crucial level. Volatility.

Could more positive company news early this year help provide a near term spark?

-----

No. 3 ALBT Potential Catalyst - Company's Fusion Gene Map Technology Seen As Major Breakthrough

Avalon GloboCare Announces the Deployment of Breakthrough Fusion Gene Map Technology

Enabling the Development and Commercialization of Companion Diagnostics and Novel Therapeutic Targets for Leukemia Patients

FREEHOLD, N.J., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a leading global developer of innovative cell-based technologies and therapeutics and laboratory testing provider, today announced that it has deployed a breakthrough fusion gene map technology to be used for the goal of developing companion diagnostic kits and devices to enhance personalized clinical management of leukemia patients.

In collaboration with the Lu Daopei Institute of Hematology, a fusion gene map database from over 1,000 patients with leukemia was established and the results were previously published in the Blood Cancer Journal. Fusion genes are important genetic abnormalities in leukemia. Using advanced gene sequencing technology, called “Whole Transcriptome Sequencing” (WTS), multiple previously unknown fusion genes were identified which may potentially establish novel diagnostic and therapeutic targets.

Fusion genes are crucial in the diagnosis and treatment of leukemia. All well-known fusion genes are founder variations and constitute critical causative factors and can serve as important indicators of disease diagnosis,” stated David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon GloboCare. “Avalon is applying the bioinformatics from the fusion gene map with the goal of accelerating the development and commercialization of companion diagnostic kits and devices to enhance personalized clinical management of leukemia patients. The first diagnostic prototype is expected to enter clinical study and regulatory filing stage during Q3 of 2023. The fusion gene map technology also provides an unprecedented opp. to identify and validate fusion gene products as potential novel therapeutic targets. Additionally, this gives us an opp. to expand Avalon’s R&D pipeline and intellectual property portfolio.

Read the full article here.

-----

No. 4 ALBT Potential Catalyst - Oversold Technicals Could Signal Huge Bounce Potential Near Term

As of 4:00PM EST Tuesday, Barchart was reporting this profile to have several oversold leaning technicals.

These technicals could be signaling a healthy reversal in the near term.

Here's the definition of a "reversal" from Investopedia:

"A reversal is a change in the price direction of an asset. A reversal can occur to the upside or downside. Following an uptrend, a reversal would be to the downside. Following a downtrend, a reversal would be to the upside. Reversals are based on overall price direction and are not typically based on one or two periods/bars on a chart."

Now, here are some key technicals (as of 4:00PM EST Tuesday) that could signal ALBT to be leaning oversold and on the verge of a potential reversal.

  • 9-Day Relative Strength Index: 30.73%
  • 14-Day Relative Strength Index: 36.58%

When these numbers drop down to the 30% range and lower, they can be viewed as being in oversold territory. While in this territory, they can paint the picture of a profile that is undervalued.

Keep an eye on these technicals closely.

-----

ALBT Recap: These Potential Catalysts Could Fuel A Vertical Move For This 5X Champ

No. 1 - Tuesday's Game-Changing Patent News Has So Far Gone Under The Radar...

No. 2 - A Low Float Could Allow For Explosive Volatility (Daily)

No. 3 - Company's Fusion Gene Map Technology Seen As Major Breakthrough

No. 4 - Oversold Technicals Could Signal Huge Bounce Potential Near Term

-----

Coverage is officially reinitiated on ALBT. When time permits, do this:

image

Get ALBT on your radar now.

Sincerely,

Kai Parker

StockWireNews


(Always Remember The Stock Prices Could Be Significantly Lower Now From The Dates I Provided.)

StockWireNews (stockwirenews . com) is owned by SWN Media LLC, a limited liability company. Disclosure: I am not a lice.nsed finan.cial adviser. Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. StockWireNews full disclosure is to be read and fully understood before using StockWireNews website, or joining StockWireNews' email or text list. By viewing StockWireNews website and/or reading StockWireNews email or text newsletter you are agreeing to StockWireNews full disclosure which can be read at www.stockwirenews.net/disclosure An owner of SWN Media LLC owns and operates smallcapfirm . com (“SCF”), owns and operates fierceinvestor . com (“FI”), and owns and operates stockstreetwire . com ("SSW"). From time to time, StockWireNews, SCF, FI, and/or SSW will publicly disseminate information about a company via website, email, SMS and other points of media. Ownership of "FI" and "SSW" has now moved to a single individual. Avalon GlobalCare Corp. previously changed its ticker symbol from (AVCO) to (ALBT). Pursuant to an agreement between SWN Media LLC and Legends Media LLC, StockWireNews has been hired for a period beginning on 1/31/22 and ending on 2/1/22 to publicly disseminate information about (AVCO) via Website, Email and SMS. SWN Media LLC was paid twenty-seven thousand five hundred USD via bank wire transfer. We own zero shares of (AVCO). Pursuant to an agreement between SWN Media LLC and TD Media LLC, StockWireNews has been hired for a period beginning on 8/3/22 and ending on 8/4/22 to publicly disseminate information about (AVCO) via Website, Email and SMS. SWN Media LLC was paid seven thousand five hundred USD via bank wire transfer. We own zero shares of (AVCO). Pursuant to an agreement between SWN Media LLC and TD Media LLC, StockWireNews has been hired for a period beginning on 10/9/22 and ending on 10/11/22 to publicly disseminate information about (AVCO) via Website, Email and SMS. SWN Media LLC was paid two thousand five hundred USD via bank wire transfer. We own zero shares of (AVCO). Pursuant to an agreement between SWN Media LLC and TD Media LLC, StockWireNews has been hired for a period beginning on 11/8/22 and ending on 11/9/22 to publicly disseminate information about (AVCO) via Website, Email and SMS. SWN Media LLC was paid ten thousand USD via bank wire transfer. We own zero shares of (AVCO). Pursuant to an agreement between SWN Media LLC and TD Media LLC, StockWireNews has been hired for a period beginning on 12/18/22 and ending on 12/20/22 to publicly disseminate information about (ALBT) via Website, Email and SMS. SWN Media LLC was paid five thousand USD via bank wire transfer. We own zero shares of (ALBT). Pursuant to an agreement between SWN Media LLC and TD Media LLC, StockWireNews has been hired for a period beginning on 1/17/23 and ending on 1/18/22 to publicly disseminate information about (ALBT) via Website, Email and SMS. SWN Media LLC was paid five thousand USD via bank wire transfer. We own zero shares of (ALBT). To date we have been compensated a total of fifty-seven thousand five hundred USD via bank wire transfer to disseminate information about (ALBT). A member of SWN Media LLC is also a member of TD Media LLC. Pursuant to an agreement between TD Media LLC and Exchange Listing LLC, TD Media LLC has been hired for a period beginning on 01/05/2023 and ending on 03/08/2023 to publicly disseminate information about (ALBT:US) via digital communications. We have been paid an additional one hundred thousand dollars USD via bank wire transfer. To date we have been paid six hundred ten thousand dollars USD via bank wire transfer to disseminate information about (ALBT:US) via digital communications. We own zero shares of (ALBT:US). lifewatermedia.com/albt-disclosure-31/